Pfizer (PFE) Stock Price & Analysis

PFE$28.89+0.06 +0.21%
Drug Manufacturers - GeneralLarge CapValue Stock
Compare
Market cap$164.67BEnterprise value$236.34BRevenue (TTM)$63.62BMarket positionTop 25%

Score

51
Neutral
Value
64
Quality
57
Growth
31

AI Analysis

Snapshot

Pfizer reads as an income name — Stocklytics 51/100, with a 5.6% dividend yield in the thesis. Under the hood: P/E 43.6, rich vs its own history, plus revenue compounding ~-12% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

64
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

31
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

57
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Pfizer Inc. (PFE) last printed $28.89. Equity value is $164.67B. Trailing earnings multiple 40.83. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$52.82B$52.55B$40.83B$40.91B$41.65B$81.29B$101.17B$59.55B$63.63B$62.58B

About

Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.

Pfizer (PFE) Stock Price & Analysis

PFE price $28.89 +0.06 +0.21%

Ticker
PFE
Price
$28.89
Change
+0.06 +0.21%
Market cap
$164.67B
P/E
40.83
Forward P/E
10.20
Dividend yield
5.59%
Beta
0.30
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
51
Value
64
Quality
57
Growth
31

Stocklytics score rationale: value 64, quality 57, growth 31.

AI Score 55. Pfizer Inc. has a market cap of approximately $174.8 billion and a price of $30.67, but its price-to-earnings ratio is high at about 42.4, indicating potential overvaluation

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener